Financial Performance - The group recorded revenue of approximately HKD 710,873,000 for the six months ended June 30, 2022, a decrease from HKD 721,974,000 in the same period of 2021[5]. - The group reported a loss of approximately HKD 6,824,000 for the six months ended June 30, 2022, compared to a profit of HKD 24,675,000 in the same period of 2021[5]. - The fair value gain on investment properties decreased to approximately HKD 886,000, down from HKD 49,175,000 in the previous year[9]. - The share of losses from associates amounted to approximately HKD 11,243,000, a shift from a profit of HKD 14,165,000 in the same period of 2021[10]. - Revenue for the six months ended June 30, 2022, was HKD 710,873,000, a decrease of 1.53% from HKD 721,974,000 in the same period of 2021[83]. - Gross profit for the same period was HKD 188,082,000, down 21.97% from HKD 241,036,000 year-on-year[83]. - Basic and diluted loss per share was HKD 0.34, compared to earnings of HKD 0.07 per share in the prior year[84]. - The company reported a loss before tax of HKD 25,763,000 for the first half of 2022, compared to a profit of HKD 51,319,000 in the same period of 2021[130]. - The company’s total comprehensive income for the six months ended June 30, 2022, was HKD 3,855,035,000, a decrease from HKD 4,154,633,000 in the previous year[98]. Revenue Sources - The group's Hong Kong medical network management business generated revenue of approximately HKD 201.97 million, representing about 28.41% of total revenue for the first half of 2022[17]. - Revenue from general, specialist, and dental medical services was approximately HKD 270,217,000, representing about 38.01% of total revenue, an increase from 29.65% in 2021[20]. - Revenue from Hong Kong medical services was HKD 270,217,000, an increase from HKD 214,056,000 in the previous year, representing a growth of about 26.2%[116]. - Revenue from mainland China hospital management and medical services was HKD 233,613,000, up from HKD 217,097,000, indicating an increase of approximately 7.6%[116]. Operational Impact of COVID-19 - The significant decline in revenue was primarily attributed to a decrease in COVID-19 testing services[8]. - The fifth wave of the pandemic and government-imposed social distancing measures severely impacted consumer activity and the economic atmosphere in Hong Kong[11]. - The group continued to provide reputable healthcare services while supporting government vaccination and testing efforts during the pandemic[11]. - The group administered over 1.3 million vaccine doses in Hong Kong, accounting for approximately 7.4% of the total doses administered in the region as of June 30, 2022[12]. - The health management business in Shandong, Guangdong, and Shenzhen was impacted by varying degrees of pandemic control measures, but the management team focused on developing specialized services and expanding quality customer base[25]. Strategic Initiatives and Acquisitions - The company has agreed to acquire Central Medical for a total consideration of HKD 476,000,000, which includes HKD 356,000,000 in convertible bonds and HKD 120,000,000 in cash[50]. - The acquisition of Central Medical was completed on August 26, 2022, with a cash payment of HKD 120 million and the issuance of convertible bonds[53]. - The company plans to invest and develop multiple specialized medical centers in Hong Kong and a dental clinic chain in China by the end of 2023, with a total investment of HKD 150 million[55]. - The company aims to develop a dental chain and invest in medical clinics and hospitals in China, with a total investment of HKD 1,500 million planned by the end of 2023[59]. - The company is focusing on market expansion through strategic partnerships and acquisitions in the healthcare sector[172]. Financial Position and Assets - The group's current assets and total assets as of June 30, 2022, were approximately HKD 1,897,001,000 and HKD 4,139,977,000, respectively[5]. - As of June 30, 2022, the group's bank balance and cash amounted to approximately HKD 1,419,887,000, an increase from HKD 910,458,000 as of December 31, 2021[39]. - The group’s equity attributable to the owners was approximately HKD 3,773,354,000 as of June 30, 2022, down from HKD 3,855,035,000 as of December 31, 2021[41]. - The company’s total equity as of June 30, 2022, was HKD 4,139,977,000, down from HKD 4,225,434,000 at the end of 2021[94]. - The company’s total receivables, including other receivables and prepayments, amounted to HKD 448,936,000 as of June 30, 2022, compared to HKD 442,581,000 as of December 31, 2021[150]. Legal and Compliance Matters - The company has initiated legal proceedings in response to claims made by Profit Castle and Dr. Ye, seeking damages and other remedies[46]. - The company continues to seek legal advice regarding the Joyous Convertible Notes and related litigation matters[44]. - The company has not received any acceptable repayment proposals from Dr. Ye and Profit Castle, leading to unsuccessful negotiations regarding the overdue bill[147]. - The company has initiated legal action against Dr. Ye and Profit Castle for the recovery of the overdue bill and accrued interest[148]. - The company’s legal claims against Mr. Dai are still pending, with an appeal filed by Mr. Dai against a previous judgment[145]. Governance and Management - The company maintained compliance with the corporate governance code as of June 30, 2022, ensuring transparency and accountability to shareholders and creditors[73]. - The company appointed six new executive directors and two independent non-executive directors on June 28, 2022, increasing the total board members to eight executive directors, two non-executive directors, and four independent non-executive directors[74][77]. - The company’s audit committee reviewed the accounting principles and practices adopted by the group, ensuring alignment with financial reporting standards[77]. - The company confirmed that all directors complied with the securities trading code during the reporting period, maintaining ethical standards in trading activities[73]. Future Outlook - The management provided guidance for the next fiscal year, projecting a revenue increase of approximately 15%[172]. - Investment in research and development is expected to increase by 20% to support innovation[172]. - The overall strategy includes diversifying product offerings to meet changing consumer demands[172].

Town Health International Medical Group Limited 赓健國際醫療集團有限公司 (於開曼群島註冊成立及於百慕邊存續之有限公司) (股份代號 : 3886) 目錄 目錄 | --- | --- | |------------------------------|-------| | | 頁次 | | | 2 | | 公司資料 財務摘要 | 4 | | 管理層討論及分析 | 5 | | 權益披露 | 25 | | 企業管治 | 27 | | | | | 獨立核數師審閱報告 | 29 | | 簡明綜合損益及其他全面收益表 | 31 | | 簡明綜合財務狀況表 | 33 | | 簡明綜合權益變動表 | 35 | | 簡明綜合現金流量表 | 37 | | 簡明綜合財務報表附註 | 38 | | | 65 | 詞彙表 康健國際醫療集團有限公司 二零二一年中期報告 1 公司資料 | --- | --- | |------------------------------------|--------------------------------| | | | | 公司資料 | | ...

b Town Health International Medical Group Limited 康健國際醫療集團有限公司 (於開曼群島註冊成立及於百慕達存續之有限公司) (股份代號 : 3886) 康健國際醫療集團有限公司 2020 年報 | --- | --- | |-------|----------------------------| | | | | 目錄 | | | 2 | 公司資料 | | 4 | 行政總裁報告 | | 7 | 管理層討論與分析 | | 26 | 董事及高級管理人員個人資料 | | 29 | 環境、社會及管治報告 | | 51 | 董事會報告 | | 64 | 企業管治報告 | | 77 | 獨立核數師報告 | | 86 | 綜合損益及其他全面收益表 | | 87 | 綜合財務狀況表 | | 89 | 綜合權益變動表 | | 91 | 綜合現金流量表 | | 93 | 綜合財務報表附註 | | 213 | 主要物業資料 | | 214 | 財務摘要 | | 215 | 詞彙表 | 1 康健國際醫療集團有限公司 2020 年報 | --- | --- | |----------- ...

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability) (Stock Code : 3886) Town Health International Medical Group Limited 康健國際醫療集團有限公司 （於開曼群島註冊成立及於百慕達存續之有限公司） （股份代號 : 3886） 2020中期報告 Interim Report 2020 目錄 目錄 | --- | --- | |------------------------------|-------| | | 頁次 | | 公司資料 | 2 | | 財務摘要 | 4 | | 管理層討論與分析 | 5 | | 權益披露 | 24 | | 企業管治 | 26 | | 獨立核數師審閱報告 | 28 | | 簡明綜合損益及其他全面收益表 | 30 | | 簡明綜合財務狀況表 | 32 | | 簡明綜合權益變動表 | 34 | | 簡明綜合現金流量表 | 36 | | 簡明綜合財務報表附註 | 37 | | 詞彙表 | 64 | 1 康健國 ...

@ Town Health International Medical Group Limited 康健國際醫療集團有限公司 (於開曼群島註冊成立及於百慕達存續之有限公司) (股份代號 : 3886) 0 (Q) 0 Vice Page T F - 1000 rs. e i 0110 milli mil mill TIME TML Finin 蒲而 THE TSTON → | A Dr Vio & Partners l Dan and momm THE POLICITIE T 10 0 OHTH THE OFFICE OF THE indom 10000 TIME T FIFIE 11017710 0 ● 康健國際醫療集團有限公司 2019 年報 | --- | --- | |-------|----------------------------| | | | | | | | 目錄 | | | 2 | 公司資料 | | 5 | 行政總裁報告 | | 9 | 管理層討論與分析 | | 23 | 董事及高級管理人員個人資料 | | 28 | 環境、社會及管治報告 | | 49 | 董事會報告 | | 63 | ...

L Town Health International Medical Group Limited 康健國際醫療集團有限公司 (於関曼群島註冊成立及於百慕建得續之有限公司) (股份代號 : 3886) OWN FILALTE 网 器科生与用品 Q (0) C SEAR GENER UR ■ 图 中期報告 2 目錄 目錄 頁次 公司資料 2 財務摘要 4 管理層討論與分析 5 權益披露 21 企業管治 25 獨立核數師審閱報告 28 簡明綜合損益及其他全面收益表 30 簡明綜合財務狀況表 32 簡明綜合權益變動表 34 簡明綜合現金流量表 36 簡明綜合財務報表附註 37 詞彙表 66 1 康健國際醫療集團有限公司 二零一九年中期報告 公司資料 公司資料 | --- | --- | |----------------------------------------------|-------------------------------------------| | 董事會 | 薪酬委員會 | | 執行董事 | 何國華先生， 榮譽勳章 （主席） | | 蔡加怡小姐 （主席） | 于學忠先生 | | 許家驊醫生 ...

Town Health International Medical Group Limited 康健國際醫療集團有限公司 (於開曼群島註冊成立及於百慕達存續之有限公司) (股份代號 : 3886) 南阳瑞视眼科医院 康健國際醫療集團有限公司 2018 年報 | --- | --- | |-------|----------------------------| | | | | 目錄 | | | 2 | 公司資料 | | 4 | 主席報告 | | 8 | 管理層討論與分析 | | 21 | 董事及高級管理人員個人資料 | | 27 | 環境、社會及管治報告 | | 46 | 董事會報告 | | 61 | 企業管治報告 | | 74 | 獨立核數師報告 | | 81 | 綜合損益及其他全面收益表 | | 83 | 綜合財務狀況表 | | 85 | 綜合權益變動表 | | 87 | 綜合現金流量表 | | 89 | 綜合財務報表附註 | | 208 | 主要物業資料 | | 209 | 財務摘要 | | 210 | 詞彙表 | 1 康健國際醫療集團有限公司 2018 年報 公司資料 | --- | --- | |- ...